Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03560739
What this trial is testing

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 284
Not applicableStudy completedNCT07002151
What this trial is testing

Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS Patients

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Cairo University 36
Large-scale testing (Phase 3)Study completedNCT01074619
What this trial is testing

Study on Cognitive Disorders of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
University Hospital, Caen 90
Not applicableStudy completedNCT02005237
What this trial is testing

Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity

Who this might be right for
Multiple Sclerosis
Universitätsklinikum Hamburg-Eppendorf 68
Not applicableStudy completedNCT06897657
What this trial is testing

Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Novartis Pharmaceuticals 155
Post-approval studies (Phase 4)WithdrawnNCT01709812
What this trial is testing

Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals
Not applicableLooking for participantsNCT07318129
What this trial is testing

Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Glostrup University Hospital, Copenhagen 220
Post-approval studies (Phase 4)Ended earlyNCT02575365
What this trial is testing

Effect of Fingolimod on Neurodegeneration

Who this might be right for
CognitionBrain Volume Loss
Novartis Pharmaceuticals 4
Testing effectiveness (Phase 2)WithdrawnNCT07006805
What this trial is testing

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis (RMS)Progressive Multiple Sclerosis (PMS)Multiple Sclerosis - Relapsing Remitting+4 more
Cabaletta Bio
Not applicableStudy completedNCT05345288
What this trial is testing

Effect of Computerized Cognitive Training in Persons With MS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University of Nebraska 53
Early research (Phase 1)Study completedNCT00813969
What this trial is testing

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

Who this might be right for
Relapsing-Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis
The Cleveland Clinic 24
Not applicableStudy completedNCT02588053
What this trial is testing

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

Who this might be right for
Multiple Sclerosis
University of Colorado, Denver 85
Large-scale testing (Phase 3)Study completedNCT00451451
What this trial is testing

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 1,417
Post-approval studies (Phase 4)Ended earlyNCT01701856
What this trial is testing

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Claudio Gobbi 5
Not applicableStudy completedNCT07346924
What this trial is testing

Effect of Probiotics on Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS) Relapsing Remitting
Cairo University 60
Early research (Phase 1)UnknownNCT00411723
What this trial is testing

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-Remitting
Artielle ImmunoTherapeutics 34
Large-scale testing (Phase 3)Ended earlyNCT01499667
What this trial is testing

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Novartis Pharmaceuticals 142
Large-scale testing (Phase 3)Active Not RecruitingNCT03477500
What this trial is testing

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

Who this might be right for
Multiple Sclerosis
Haukeland University Hospital 100
Post-approval studies (Phase 4)Ended earlyNCT01755871
What this trial is testing

Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Heinrich-Heine University, Duesseldorf 8
Not applicableStudy completedNCT07624812
What this trial is testing

Behavioral and Electrophysiological Evidence of the Modulation of Fatigue in RR-MS

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Istituto Auxologico Italiano 36
Next Page